ABSTRACT: Fertility issues have become critical in the management and counseling of BRCA mutation carriers. In this setting four points deserve consideration. (1) Women in general lose their ability to conceive at a mean age of 41 years, thus the suggested policy of prophylactic bilateral salpingo-oophorectomy at age 40 for BRCA mutation carriers does not affect the chances of natural pregnancy. Conversely, if the procedure is chosen at 35 years old, oocyte cryopreservation prior to surgery should be considered. (2) Some evidence suggests that ovarian reserve may actually be partly reduced in BRCA mutations carriers and that the mutation may affect ovarian responsiveness to stimulation. However, these findings are still controversial. (3) Breast cancer is not rare before the age of 40 and fertility preservation after diagnosis can be requested in a significant proportion of BRCA mutation carriers. Thus, a policy of oocyte cryopreservation in young healthy carriers deserves consideration. The procedure could be considered at a young age and in an elective setting, when ovarian stimulation may yield more oocytes of better quality. (4) Preimplantation genetic diagnosis (PGD) could be considered in BRCA mutations carriers, particularly when good quality oocytes have been stored at a young age. Based on the current knowledge, a univocal approach cannot be recommended; in depth patient counseling is warranted.
Introduction
The identification of a causative link between BRCA1 and 2 mutations and hereditary breast and ovarian tumors has led to the development of both successful preventive strategies for early detection of malignancies and novel prophylactic approaches (Llort et al., 2015; Powell, 2015; Ring et al., 2017) . Healthy BRCA1 and 2 mutation carriers are at risk of premature ovarian failure related to a potentially impaired ovarian reserve and/or to the development of breast/ovarian cancer at young age. In particular, the gonadotoxic effects of chemotherapy may significantly compromise reproductive potential in cancer patients with BRCA1 and 2 mutations. Thus, the need for shared and rational fertility counseling and management is of utmost importance (Kondylakis et al., 2013; Pravettoni et al., 2016) .
The aim of this paper is to give a critical and comprehensive overview of the factors that could potentially influence the process of fertility counseling in BRCA-mutated women, excluding the issue of oocyte donation.
Reduction of ovarian cancer risk
The lifetime risk of developing ovarian cancer ranges from 36% to 63% and from 10% to 27% for BRCA1 and BRCA2 mutation carriers, respectively (Kauff et al., 2002; Callahan et al., 2007; Rebbeck et al., 2009a; Domchek et al., 2010a; Daly et al., 2016) . BRCA1 carriers usually develop ovarian cancer at a younger age, even if the absolute risk during reproductive years remains low (Chen, Parmigiani, 2007; Bolton et al., 2012) . A recent prospective study showed that the cumulative risk of ovarian cancer before 40 years of age is 2% for BRCA1 and close to 0% for BRCA2 (Kuchenbaecker et al., 2017) .
Once a BRCA mutation is detected, increasing surveillance, starting chemoprevention with tamoxifen or oral contraceptives (Moorman et al., 2013) or undergoing risk-reducing surgery (RRSO: risk-reducing salpingo-oophorectomy and RRM: risk-reducing mastectomy) may reduce the risk of developing breast or ovarian cancer. Interestingly, the benefits of oophorectomy in BRCA mutation carriers may also include reduction of breast cancer incidence and mortality (Kauff et al., 2008; Domchek et al., 2010b) . Even if the data on breast cancer protection have been questioned by some authors (Heemskerk-Gerritsen et al., 2015) , a recent reanalysis of the original results confirmed a significant reduction of risk (Chai et al., 2015) . Interestingly, Kotsopoulos et al. (2016) recently suggested that the reduction of breast cancer incidence might be limited to BRCA2 carriers. Overall, it appears reasonable to suggest RRSO at the age of 35-40 and 40-45 in BRCA1 and BRCA2 mutation carriers, respectively. This approach would reduce the risk of ovarian cancer by approximately 80-90% (Rebbeck et al., 2009b) and of breast cancer by 60% (Domchek et al., 2010b) .
Postponing the age of RRSO is clinically relevant not only for reproductive concerns, but also to delay surgical menopause. The decrease of estrogen and androgen levels after RRSO causes vasomotor symptoms, vaginal dryness, dyspareunia, mood swings and cognitive impairment that can severely impair quality of life. Premature menopause may also increase the risk of ischemic heart disease, osteoporosis and associated bone fractures, neurocognitive disorders, cancers or suicide (De Vos et al., 2010; Faubion et al., 2015) . Notably, hormone replacement therapy (HRT) can be considered in healthy BRCA mutation carriers to overcome these consequences (Birrer et al., 2016) .
RRSO at 40 years old combines effectiveness in cancer risk reduction (Kuchenbaecker et al., 2017) and respect of reproductive needs. Natural fecundity declines with age and the end of fertility anticipates the advent of natural menopause in about 10 years, occurring at a median age of 51 (Te Velde and Pearson, 2002; Eijkemans et al., 2014) . In general, all women should be aware that postponing pregnancy decreases the chance of parenthood. This is even more important in BRCA1 carriers who may opt for RRSO at 35 years. Notably, assisted reproductive technologies are unable to overcome the detrimental effects of time (Somigliana et al., 2016) and the chance of success of these techniques steadily declines with age. In other words, RRSO at 40 cannot significantly impair the reproductive potential of BRCA mutation carriers, as most women will be very close to the natural end of their fertility. Consequently, performing oocyte cryopreservation at 40 years old, just before RRSO, may not be effective as only a few and low quality oocytes can usually be retrieved. Conversely, oocyte cryopreservation could be an option for women at an earlier age.
Three additional issues complicate the scenario and will be addressed in the following paragraphs: (i) the recently emerging evidence of a possible reduced ovarian reserve in BRCA carriers, (ii) the need for oncologic gonadotoxic treatments if breast cancer is diagnosed at young age and (iii) the possibility of preventing BRCA transmission to offspring with the use of preimplantation genetic diagnosis (PGD).
Ovarian reserve and fertility BRCA1 and 2 are members of the ATM (ataxia teleangectasia mutated)-mediated double strand break (DSB) repair family genes. BRCA1 is highly expressed in germ cells and blastocysts, suggesting a possible role in gametogenesis and embryogenesis (Pal et al., 2010) . In the resting oocytes of BRCA mutation carriers, it has been suggested that DNA damage may accumulate over time leading to apoptosis and an accelerated decrease in ovarian reserve.
Some experimental evidence supports the relation between a proficient DNA DSB repair and ovarian reserve. In BRCA1 mutated mice, primordial follicle counts and AMH levels are lower and follicular DSBs are increased compared to normal controls (Titus et al., 2013) . In humans, the data are less clear (Shapira et al., 2015a) . Some authors have reported a reduced ovarian reserve in BRCA1 mutations carriers (Rzepka-Górska et al., 2006; Oktay et al., 2010; Lin et al., 2013; Titus et al., 2013; Wang et al., 2014; Giordano et al., 2016) while others have observed no difference (Pal et al., 2010; Collins et al., 2014; Finch et al., 2013; Michaelson-Cohen et al., 2014; van Tilborg et al., 2016) . Results of the available studies are summarized in Table I .
Ovarian reserve and natural fertility decline in parallel, however a clear relation between the two remains questionable. Steiner et al. (2011) observed a significantly reduced natural fecundity in women with AMH <0.7 ng/mL, but subsequent contributions failed to document an association between AMH levels and time to conception (Hagen et al., 2012; Streuli et al., 2014; Somigliana et al., 2015; Steiner et al., 2017) . A well-conducted reproductive epidemiology study showed that BRCA mutation carriers had 1.2 times more children than controls and that they were 2.7 times more likely to have four or more children (Smith et al., 2012) . Another case-control study ended up with similar results (Pal et al., 2010) and a recent paper reported increased fecundity also in men (Kwiatkowski et al., 2015) . Reasons for this improved natural fecundity are unknown.
The possible lower ovarian reserve associated with a normal fecundity is not a contradictory finding. One may speculate that women with BRCA mutations may have lower ovarian reserve, but a relatively earlier onset of menopause does not impair fertility. As mentioned, women in their fifth decade of life are infertile despite having ovulating cycles due to the age-related reduction in the quality of the oocytes (Te Velde and Pearson, 2002) . For this reason, the debate on the possible modest reduction in ovarian reserve in BRCA mutations carriers is of doubtful relevance for natural fertility. On the other hand, the success of assisted reproduction partly depends on the number of oocytes that can be retrieved after each cycle of stimulation, which does correlate with ovarian reserve (Broer et al., 2013; Iliodromiti et al., 2014) . If solid evidence of a significant reduction of ovarian reserve does emerge, a reduced effectiveness of assisted reproduction techniques, including oocyte cryopreservation, could be expected in BRCA mutations carriers.
Impact of breast cancer occurrence on fertility
The mean age at diagnosis of breast cancer for BRCA1 and BRCA2 mutation carriers is 43 and 47 years, respectively (van der Kolk et al., 2010) , with a relevant number of cases diagnosed before age 35. The EMBRACE study prospectively followed 988 women with BRCA mutations for breast cancer occurrence (Mavaddat et al.,2013) . In BRCA1 carriers, an incidence per year of 10/1000 in women between 20 and 29 years, 17/1000 between 30 and 39, 20/1000 between 40 and 49 years, and 36/1000 between 50 and 59 was reported. For BRCA2 carriers, the incidence peaked in the group aged 40 and 49 (41/1000 cases per year), ranging between 12 and 16/1000 per year for the other age groups (Mavaddat et al.,2013) . In a recent prospective study by Kuchenbaecker et al. (2017) the cumulative risk of developing breast cancer between 31 and 40 years was 24% (95%CI: 21-29%) and 13% (95%CI: 9-19%) for BRCA1 and BRCA2 mutation carriers, respectively.
Bilateral mastectomy can reduce the risk of developing breast cancer by as much as 90%, and is endorsed by many guidelines (Rebbeck et al., 2004; Domcheck et al., 2010b; De Felice et al., 2015) . However, at present, the uptake of bilateral mastectomy is generally low, with only 18% of all patients performing the procedure at a mean age of 41 years (Metcalfe et al., 2008) , although a recent paper reported higher rates (46%), regardless of the type of BRCA mutation (Chai et al., 2015) . Therefore, most BRCA mutations carriers may face a breast cancer diagnosis during their reproductive lifespan. This group of patients usually request gonadotoxic chemotherapy and/or adjuvant hormonal treatment for 5-10 years. Thus, most BRCA carriers diagnosed with breast cancer before 40 years become candidates for fertility preservation (Peccatori et al., 2013) .
However, in this setting the procedure becomes urgent, even if generally there is sufficient time to set up a cycle of ovarian stimulation before treatment. On the other hand, the number of oocytes that can be retrieved in a single cycle is generally insufficient to ensure a good chance of success, especially in older women and/or in those with a reduced ovarian reserve. The recent development of random start double stimulation protocols may partly overcome this limitation (Kuang et al., 2014) . Ovarian freezing is an alternative option (De Vos et al., 2014) , although this technique is also influenced by ovarian reserve and re-implantation of tissue which is at risk of cancer remains an issue.
In this context, the availability of oocytes cryopreserved at a younger age would be beneficial; ovarian stimulation would not always be necessary and an increased number of cryopreserved oocytes would allow higher chances of success (Broer et al., 2013; Iliodromiti et al., 2014) . Notably, in experienced hands, storing more than 15 oocytes in young women would ensure an 85% chance of live birth (Cobo et al., 2016) . In the clinical management of young women with a history of breast cancer, a crucial aspect that should receive attention is the timing of a subsequent pregnancy. Pregnancy does not impair breast cancer prognosis (Danforth, 1991; Velentgas et al.,1999; Rosenberg et al. 2004; Azim et al., 2013) , but there is a general consensus that childbearing should be delayed until 3-5 years after completion of treatment. However, this recommendation might vary according to cancer biology and stage (Averette et al., 1999; Ives et al., 2007) . Here age plays an essential role, since delaying pregnancy for women in their late thirties or for those with reduced ovarian reserve might definitively impair fertility. In patients with endocrine responsive tumors, who are candidates for a 5-10 years adjuvant treatment (Davies et al., 2013) , the timing of pregnancy is also controversial, although studies assessing the possibility of a temporary interruption of endocrine therapy are ongoing (Pagani et al.,2015) .
Prevention of BRCA transmission with preimplantation genetic diagnosis: PGD Carrying a BRCA mutation is not a disease, but a situation that increases the risk of developing breast and ovarian cancer later in life. As all autosomal dominant conditions, it implies a 50% risk of transmission to offspring; its penetrance is variable, and a proportion of women with the mutations will not develop cancer in their entire life. These considerations have raised some concerns for the use of PGD in BRCA mutation carriers, but the possible health and psychological consequences of this particular condition have overcome these uncertainties. In fact, in 2003 the European Society of Human Reproduction and Embryology (ESHRE) ethics taskforce considered PGD acceptable for conditions like hereditary breast and ovarian cancer (Shenfield et al., 2003) . Accordingly, PGD for BRCA mutations is growing and has become the most common indication in some settings (GietelHabets et al., 2017) , but the awareness regarding its availability varies among countries and is still low (Quinn et al., 2012; Gietel-Habets et al., 2017) . Nonetheless, a recent survey of 1081 BRCA mutation carriers highlighted that patients are keen to have reproductive counseling, with 59% stating that PGD should be offered (Chan et al. 2017) . PGD is not a therapy per se, as it solely selects unaffected embryos. As with any other ART technique, its effectiveness is related to the woman's age and to the number of available oocytes. Here it is relevant to state that 25% if not 50% (if we exclude also male embryos with the mutations) of otherwise healthy embryos have to be discarded in a PGD program for BRCA mutations. In this scenario, it seems more appropriate to discuss the possibility of PGD in women carrying BRCA mutation early on in their life. In women refusing the possibility of transmitting the mutation to their offspring, oocytes cryopreservation should be considered at young age, possibly before 30 years old. Even if the age limit of 30 is merely speculative, it is noteworthy that, by this age, the number of women who have developed cancer is still very low, the effectiveness of assisted reproduction is still optimal and a consistent proportion of women may have already had children. A strategy of oocyte cryopreservation at young age would anticipate the detrimental effects of the reduced ovarian reserve and would allow the storage of a high number of top quality oocytes. However one concern that needs to be discussed is the possibly increased risk of breast and ovarian cancer associated with the use of gonadotropins for ovarian stimulation, although the available data on the relation between ovarian stimulation and breast or ovarian cancers is more and more reassuring (Siristatidis et al., 2013; Sergentanis et al., 2014) . In addition to this, the available evidence on BRCA carriers, albeit less robust, has failed to document any significant association of ovarian stimulation with increased breast and ovarian cancer risk (Kotsopoulos et al., 2008; Perri et al., 2015; Gronwald et al., 2016) .
Conclusions
The health impacts of a BRCA mutation have been extensively investigated and ongoing studies aimed at disentangling the most suitable strategy for clinical management of carriers will soon provide additional information. In general, BRCA carriers are currently offered a rich panel of effective options that can markedly shrink their overall risk of cancer diagnosis and cancer mortality. In this context, ensuring parenthood has also become a priority. Several options are now available and women should receive comprehensive information to reach a shared decision. Women should be informed in depth about possible advantages of oocyte cryopreservation given their condition of being a BRCA mutation carrier (distinguishing BRCA1 and BRCA2) but also about the general risks, cost and effectiveness of the procedure. Regardless of the unresolved debate on the impact of BRCA mutation on ovarian reserve, a personalized assessment of serum AMH or antral follicle count at the time of counseling may also be useful. Finally, given the long-lasting situation of the carriers, physicians should consider the possibility of dynamic counseling over time, considering that women's aspirations may modify with age. Overall, based on current knowledge, standardized clinical management cannot be recommended. However, even if a policy of fertility preservation at young age in healthy BRCA carriers cannot be firmly advocated, it deserves consideration and should be carefully discussed with each woman.
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